Relief Therapeutics Holding SA (SWX:RLF)
3.070
-0.080 (-2.54%)
Mar 3, 2025, 5:31 PM CET
SWX:RLF Revenue
Relief Therapeutics Holding had revenue of 3.01M CHF in the half year ending December 31, 2023, a decrease of -9.36%. This brings the company's revenue in the last twelve months to 8.60M, up 45.04% year-over-year. In the year 2023, Relief Therapeutics Holding had annual revenue of 6.03M, down -0.79%.
Revenue (ttm)
8.60M
Revenue Growth
+45.04%
P/S Ratio
4.46
Revenue / Employee
175.47K
Employees
49
Market Cap
38.50M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 62.40B |
Novartis AG | 46.87B |
Alcon | 8.98B |
Lonza Group AG | 6.57B |
Galderma Group AG | 3.88B |
Straumann Holding AG | 2.50B |
Sandoz Group AG | 9.09B |
Sonova Holding AG | 3.71B |
Relief Therapeutics Holding News
- 20 days ago - Relief Therapeutics to get European patent for investigational drug RLF‑TD011 - Seeking Alpha
- 20 days ago - Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 - Accesswire
- 5 weeks ago - Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US - Accesswire
- 5 weeks ago - Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US - Accesswire
- 2 months ago - Relief Therapeutics advances merger talks with Renexxion - Seeking Alpha
- 2 months ago - Relief Therapeutics Provides Update on Potential Transaction with Renexxion - Accesswire
- 2 months ago - Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial - Accesswire
- 2 months ago - Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations - Accesswire